Alkermes plc Insider Trading

ALKS

Last 12 months

Insiders sold $10.1M and bought nothing on the open market.

71% of the selling was scheduled in advance under 10b5-1 plans. Director Nancy Lynn Md Snyderman sold $2.24M on Aug 3, 55% of their stake, outside a plan. The last open-market buy by an executive or director was in Nov 2022.

Net open-market

−$10.1M

0 buys · 28 sales

Under a 10b5-1 plan

71%

of the value sold

Insiders who bought / sold

0 / 7

executives and directors

Last open-market buy

Nov 2022

Nov 14, 2022

Get an email when ALKS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 3	David Joseph Gaffin EVP, CLO, Alkermes, Inc.	Sold10b5-1 plan	2,035	$46.17	94K	0.9%	Form 4
Oct 2	David Joseph Gaffin EVP, CLO, Alkermes, Inc.	Sold10b5-1 plan	2,034	$41.03	83K	0.9%	Form 4
Sep 3	David Joseph Gaffin EVP, CLO, Alkermes, Inc.	Sold10b5-1 plan	2,034	$48.01	98K	0.9%	Form 4
Sep 1	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	9,000	$46.99	423K	12%	Form 4
Aug 17	Christian Todd Nichols SVP, Chief Commercial Officer	Sold10b5-1 plan 2 parts	7,576	$49.23 average	373K	6.9%	Form 4
Aug 3	Nancy Lynn Md Snyderman Director	SoldNo plan	44,472	$50.35	$2.24M	55%	Form 4
Aug 3	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	9,000	$48.58	437K	11%	Form 4
Aug 3	David Joseph Gaffin EVP, CLO, Alkermes, Inc.	Sold10b5-1 plan	2,034	$48.58	99K	0.9%	Form 4
Jul 6	David Joseph Gaffin EVP, CLO, Alkermes, Inc.	Sold10b5-1 plan	2,034	$54.03	110K	0.9%	Form 4
Jul 1	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan 2 parts	9,000	$51.51 average	464K	11%	Form 4
Jun 12	Christopher I Wright Director	Sold10b5-1 plan	2,000	$45.10	90K	7.2%	Form 4
Jun 4	David Joseph Gaffin EVP, CLO, Alkermes, Inc.	Sold10b5-1 plan	2,034	$43.05	88K	0.9%	Form 4
Jun 1	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	9,000	$41.67	375K	10%	Form 4
May 29	Samuel Joseph Parisi VP, Finance (Interim PAO)	SoldNo plan	16,217	$42.36	687K	68%	Form 4
May 4	David Joseph Gaffin EVP, CLO, Alkermes, Inc.	Sold10b5-1 plan	2,034	$33.20	68K	0.9%	Form 4
May 1	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	9,000	$33.40	301K	10.0%	Form 4
Apr 6	David Joseph Gaffin EVP, CLO, Alkermes, Inc.	Sold10b5-1 plan	2,034	$34.57	70K	0.9%	Form 4
Apr 1	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	9,000	$35.51	320K	9.5%	Form 4
Mar 2 – 3	David Joseph Gaffin EVP, CLO, Alkermes, Inc.	Sold10b5-1 plan 2 parts	4,068	$29.53 average	120K	1.7%	Form 4
Mar 2	Samuel Joseph Parisi VP, Finance (Interim PAO)	Sold10b5-1 plan	6,890	$29.29	202K	47%	Form 4
Mar 2	Christian Todd Nichols SVP, Chief Commercial Officer	Sold10b5-1 plan	6,000	$30.00	180K	5.2%	Form 4
Mar 2	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	9,000	$29.72	267K	9.1%	Form 4
Feb 2	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan 2 parts	9,000	$33.93 average	305K	13%	Form 4
Feb 2	Shane Cooke Director	Sold10b5-1 plan 2 parts	61,200	$34.57 average	$2.12M	37%	Form 4
Jan 8	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	5,000	$30.00	150K	7.5%	Form 4
Jan 2	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	4,000	$28.00	112K	6.1%	Form 4
Dec 3, 2025	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	3,748	$30.00	112K	5.4%	Form 4
Dec 1, 2025	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	4,000	$29.30	117K	5.7%	Form 4
Nov 3, 2025	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	9,000	$30.38	273K	11%	Form 4
Oct 15, 2025	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	9,000	$31.53	284K	11%	Form 4
Jun 9, 2025 – Jun 10, 2025	Christian Todd Nichols SVP, Chief Commercial Officer	Sold10b5-1 plan 2 parts	6,667	$31.52 average	210K	7.2%	Form 4
Feb 28, 2025	Samuel Joseph Parisi VP, Finance (Interim PAO)	Sold10b5-1 plan	1,938	$34.00	66K	20%	Form 4
Feb 25, 2025	Samuel Joseph Parisi VP, Finance (Interim PAO)	Sold10b5-1 plan	3,743	$35.26	132K	33%	Form 4
Feb 20, 2025	Samuel Joseph Parisi VP, Finance (Interim PAO)	Sold10b5-1 plan	1,327	$35.69	47K	15%	Form 4
Feb 12, 2025 – Feb 13, 2025	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan 4 parts	349,340	$33.92 average	$11.8M	86%	Form 4
Jan 30, 2025	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	100,918	$32.05	$3.23M	69%	Form 4
Dec 9, 2024	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	61,151	$32.07	$1.96M	56%	Form 4
Dec 9, 2024	Cato T Laurencin Director	Sold10b5-1 plan	2,691	$31.85	86K	10%	Form 4
Dec 5, 2024	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	9,221	$31.50	290K	13%	Form 4
Dec 4, 2024	Craig C. Hopkinson EVP R&D, Chief Medical Officer	Sold10b5-1 plan	14,349	$30.77	442K	17%	Form 4

Nov 310b5-1 plan
David Joseph Gaffin
EVP, CLO, Alkermes, Inc. · sold 2,035 at $46.17
94K
0.9% of stake
Oct 210b5-1 plan
David Joseph Gaffin
EVP, CLO, Alkermes, Inc. · sold 2,034 at $41.03
83K
0.9% of stake
Sep 310b5-1 plan
David Joseph Gaffin
EVP, CLO, Alkermes, Inc. · sold 2,034 at $48.01
98K
0.9% of stake
Sep 110b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 9,000 at $46.99
423K
12% of stake
Aug 1710b5-1 plan
Christian Todd Nichols
SVP, Chief Commercial Officer · sold 7,576 at avg $49.23
373K
6.9% of stake
Aug 3No plan
Nancy Lynn Md Snyderman
Director · sold 44,472 at $50.35
$2.24M
55% of stake
Aug 310b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 9,000 at $48.58
437K
11% of stake
Aug 310b5-1 plan
David Joseph Gaffin
EVP, CLO, Alkermes, Inc. · sold 2,034 at $48.58
99K
0.9% of stake
Jul 610b5-1 plan
David Joseph Gaffin
EVP, CLO, Alkermes, Inc. · sold 2,034 at $54.03
110K
0.9% of stake
Jul 110b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 9,000 at avg $51.51
464K
11% of stake
Jun 1210b5-1 plan
Christopher I Wright
Director · sold 2,000 at $45.10
90K
7.2% of stake
Jun 410b5-1 plan
David Joseph Gaffin
EVP, CLO, Alkermes, Inc. · sold 2,034 at $43.05
88K
0.9% of stake
Jun 110b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 9,000 at $41.67
375K
10% of stake
May 29No plan
Samuel Joseph Parisi
VP, Finance (Interim PAO) · sold 16,217 at $42.36
687K
68% of stake
May 410b5-1 plan
David Joseph Gaffin
EVP, CLO, Alkermes, Inc. · sold 2,034 at $33.20
68K
0.9% of stake
May 110b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 9,000 at $33.40
301K
10.0% of stake
Apr 610b5-1 plan
David Joseph Gaffin
EVP, CLO, Alkermes, Inc. · sold 2,034 at $34.57
70K
0.9% of stake
Apr 110b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 9,000 at $35.51
320K
9.5% of stake
Mar 2 – 310b5-1 plan
David Joseph Gaffin
EVP, CLO, Alkermes, Inc. · sold 4,068 at avg $29.53
120K
1.7% of stake
Mar 210b5-1 plan
Samuel Joseph Parisi
VP, Finance (Interim PAO) · sold 6,890 at $29.29
202K
47% of stake
Mar 210b5-1 plan
Christian Todd Nichols
SVP, Chief Commercial Officer · sold 6,000 at $30.00
180K
5.2% of stake
Mar 210b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 9,000 at $29.72
267K
9.1% of stake
Feb 210b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 9,000 at avg $33.93
305K
13% of stake
Feb 210b5-1 plan
Shane Cooke
Director · sold 61,200 at avg $34.57
$2.12M
37% of stake
Jan 810b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 5,000 at $30.00
150K
7.5% of stake
Jan 210b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 4,000 at $28.00
112K
6.1% of stake
Dec 3, 202510b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 3,748 at $30.00
112K
5.4% of stake
Dec 1, 202510b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 4,000 at $29.30
117K
5.7% of stake
Nov 3, 202510b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 9,000 at $30.38
273K
11% of stake
Oct 15, 202510b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 9,000 at $31.53
284K
11% of stake
Jun 9, 2025 – Jun 10, 202510b5-1 plan
Christian Todd Nichols
SVP, Chief Commercial Officer · sold 6,667 at avg $31.52
210K
7.2% of stake
Feb 28, 202510b5-1 plan
Samuel Joseph Parisi
VP, Finance (Interim PAO) · sold 1,938 at $34.00
66K
20% of stake
Feb 25, 202510b5-1 plan
Samuel Joseph Parisi
VP, Finance (Interim PAO) · sold 3,743 at $35.26
132K
33% of stake
Feb 20, 202510b5-1 plan
Samuel Joseph Parisi
VP, Finance (Interim PAO) · sold 1,327 at $35.69
47K
15% of stake
Feb 12, 2025 – Feb 13, 202510b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 349,340 at avg $33.92
$11.8M
86% of stake
Jan 30, 202510b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 100,918 at $32.05
$3.23M
69% of stake
Dec 9, 202410b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 61,151 at $32.07
$1.96M
56% of stake
Dec 9, 202410b5-1 plan
Cato T Laurencin
Director · sold 2,691 at $31.85
86K
10% of stake
Dec 5, 202410b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 9,221 at $31.50
290K
13% of stake
Dec 4, 202410b5-1 plan
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · sold 14,349 at $30.77
442K
17% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ALKS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ALKS

CompareIntrinsic value

SRPTSarepta Therapeutics Inc.

$18.99+2.43%51

INSMInsmed Inc.

$110.00+5.32%40

PAHCPhibro Animal Health Corporation

$39.43+4.73%57

INDVIndivior Pharmaceuticals, Inc.

$36.28+2.57%80

MDGLMadrigal Pharmaceuticals, Inc.

$400.67+1.10%10

PTCTPTC Therapeutics, Inc.

$68.97+1.25%65

ACADAcadia Pharmaceuticals Inc.

$21.49+4.47%74

APLSApellis Pharmaceuticals, Inc.

$3.10+3.29%83

Held by ETFs

ALKS is in 136 US ETFs. The largest of them, with ALKS's weight in each:

Spot a number that looks wrong? Check it in ALKS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ALKS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.